無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

癌ワクチンの世界市場:2015年〜2019年

Global Cancer Vaccines Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 333142
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
癌ワクチンの世界市場:2015年〜2019年 Global Cancer Vaccines Market 2015-2019
出版日: 2015年06月17日 ページ情報: 英文 64 Pages
概要

世界の癌ワクチン市場は、2014年〜2019年のCAGRで、27.24%の成長が見込まれています。

当レポートでは、世界の癌ワクチン市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 ワクチンの承認プロセス

第7章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 市場区分:ワクチンの臨床応用別

  • 予防ワクチン
  • 治療ワクチン

第9章 世界の予防ワクチン市場

  • 市場概要
  • 市場規模と予測

第10章 世界の治療ワクチン市場

  • 市場概要
  • 市場規模と予測

第11章 地理区分

第12章 購入基準

第13章 主要ブランド分析

  • GardasilとCervarixの比較研究

第14章 パイプラインのポートフォリオ

第15章 市場成長促進要因

第16章 成長促進要因とその影響

第17章 市場の課題

第18章 成長促進要因と課題の影響

第19章 市場動向

第20章 動向とその影響

第21章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他・将来の有力ベンダー

第22章 癌ワクチンベンダーの機会

第23章 主要ベンダー分析

  • Dendreon
  • GlaxoSmithKline
  • Merck & Co. Inc.

第24章 関連レポート

図表

図表
  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Vaccine Approval Process
  • Exhibit 3: Global Cancer Vaccines Market 2014-2019 ($ millions)
  • Exhibit 4: Segmentation of Global Cancer Vaccines Market by Clinical Application of Vaccines
  • Exhibit 5: Segmentation of Global Cancer Vaccines Market by Clinical Application of Vaccines, 2014
  • Exhibit 6: Global Prophylactic Vaccines Market 2014-2019 ($ millions)
  • Exhibit 7: Global Therapeutic Vaccines Market 2014-2019 ($ millions)
  • Exhibit 8: Segmentation of the Global Cancer Vaccines Market by Geography, 2014
  • Exhibit 9: Global Cancer Vaccines Market: Comparison of the Major Brands
  • Exhibit 10: Gardasil and Cervarix: A Comparative Study
  • Exhibit 11: Key Late-stage Vaccines Under Development
  • Exhibit 12: Drivers of the Global Cancer Vaccines Market
  • Exhibit 13: Challenges of the Global Cancer Vaccines Market
  • Exhibit 14: Trends of the Global Cancer Vaccines Market
  • Exhibit 15: Global Revenue and YoY Growth Rate of Gardasil 2010-2014
  • Exhibit 16: Global Revenue and YoY Growth Rate of Provenge 2011-2014
  • Exhibit 17: Global Revenue and YoY Growth Rate of Cervarix 2010-2014
  • Exhibit 18: Opportunity Analysis: Global Cancer Vaccine Market
  • Exhibit 19: GlaxoSmithKline: Business segmentation by revenue 2014
  • Exhibit 20: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 21: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 22: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 23: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 24: Merck & Co. Inc.: Sales by Geography 2013
目次
Product Code: IRTNTR6198

About Cancer Vaccines

Cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer.

Technavio's analysts forecast the global cancer vaccines market to grow at a CAGR of 27.24% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various therapeutic and prophylactic cancer vaccines.

This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019 in the following three regions:

  • Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
  • EMEA: The principal countries focused upon in this region are the UK; Germany; Italy; France; Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
  • APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is one of the major markets that is untapped by the leading vendors

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio's report, Global Cancer Vaccines Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global cancer vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Dendreon
  • GlaxoSmithKline
  • Merck

Other Prominent Vendors

  • Aduro BioTech
  • Advantagene
  • Advaxis
  • Agenus
  • AlphaVax
  • Altor BioScience
  • Amgen
  • Antigen Express
  • Argos Therapeutics
  • AVAX Technologies
  • Bavarian Nordic
  • Biothera
  • Bristol-Myers Squibb
  • Celldex Therapeutics
  • Cel-Sci
  • CureVac
  • Cytos
  • Galena Biopharma
  • Genexine
  • GlobeImmune
  • Gradalis
  • Heat Biologics
  • Immatics
  • ImmunoCellular Therapeutics
  • Immutep
  • Inovio Pharmaceuticals
  • Isa Pharmaceuticals
  • Juvaris Biotherapeutics
  • MedImmune
  • NewLink Genetics
  • Northwest Biotherapeutics
  • NovaRx
  • OncoThyreon
  • Oncovir
  • Oxford BioMedica
  • Prima BioMed
  • Progenics
  • Provectus Biopharmaceuticals
  • Sanofi
  • Sotio
  • Transgene
  • Ubivac
  • Vaccinogen
  • Vaxon Biotech
  • Vical

Market Driver

  • Increased Prevalence of Cancers
  • For a full, detailed list, view our report

Market Challenge

  • Cold Chain Management
  • For a full, detailed list, view our report

Market Trend

  • Strategic Alliances
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Vaccine Approval Process

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Clinical Application of Vaccines

  • 08.1. Prophylactic Vaccines
  • 08.2. Therapeutic Vaccines

09. Global Prophylactic Vaccines Market

    • 09.1.1. Market Overview
    • 09.1.2. Market Size and Forecast

10. Global Therapeutic Vaccines Market

    • 10.1.1. Market Overview
    • 10.1.2. Market Size and Forecast

11. Geographical Segmentation

12. Buying Criteria

13. Key Brand Analysis

  • 13.1. Comparative Study between Gardasil and Cervarix

14. Pipeline Portfolio

    • 14.1.1. Prostvac
    • 14.1.2. Neuvax
    • 14.1.3. Rindopepimut
    • 14.1.4. MVax
    • 14.1.5. DCVax-L
    • 14.1.6. ProstAtak
    • 14.1.7. Talimogene Laherparepvec
    • 14.1.8. IMA901
    • 14.1.9. Imprime PGG
    • 14.1.10. OncoVAX
    • 14.1.11. Lucanix
    • 14.1.12. DCVAC/PCa

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. Merck
    • 21.2.2. Dendreon
    • 21.2.3. GlaxoSmithKline
  • 21.3. Other and Future Prominent Vendors

22. Opportunities for Cancer Vaccine Vendors

23. Key Vendor Analysis

  • 23.1. Dendreon
    • 23.1.1. Key Facts
    • 23.1.2. Business Overview
    • 23.1.3. Recent Developments
    • 23.1.4. SWOT Analysis
  • 23.2. GlaxoSmithKline
    • 23.2.1. Key facts
    • 23.2.2. Business overview
    • 23.2.3. Business segmentation by revenue 2014
    • 23.2.4. Business segmentation by revenue 2013 and 2014
    • 23.2.5. Geographical segmentation by revenue 2014
    • 23.2.6. Business strategy
    • 23.2.7. Recent developments
    • 23.2.8. SWOT analysis
  • 23.3. Merck & Co. Inc.
    • 23.3.1. Key Facts
    • 23.3.2. Business Overview
    • 23.3.3. Business Segmentation by Revenue 2013
    • 23.3.4. Business Segmentation by Revenue 2012 and 2013
    • 23.3.5. Sales by Geography
    • 23.3.6. Business Strategy
    • 23.3.7. Key Developments
    • 23.3.8. SWOT Analysis
Back to Top